California-based Evommune, Inc. (NYSE: EVMN) revealed EVO756, an oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist, failed to meet its...
Read full article →Ruvonoflast (NT-0796), an oral NLRP3 inflammasome inhibitor developed by Boston-based Rezera Inc. (formerly NodThera), met its primary endpoint in the...
Mindera Health is collaborating with University of Pennsylvania researchers to investigate why quinacrine helps some patients with cutaneous lupus—and...
Durham, North Carolina-based Seismic Pharmaceuticals has launched a global Phase III trial of istaroxime in cardiogenic shock, a life-threatening condition...
Palo Alto-based UpDoc has been selected as a lead performer in the Advanced Research Projects Agency for Health (ARPA-H) ADVOCATE program, receiving an...
Jupiter, Florida-based Cytonics Corporation has completed a USD 4.8 million gross-proceeds financing campaign, bringing total capital raised to USD 47...
Lotus Neuro, a clinical-stage biotechnology company spun out of focused ultrasound specialist Insightec, launched publicly with a platform designed to...
Massachusetts-based Disc Medicine (Nasdaq: IRON) released Phase II data showing that DISC-3405, an anti-TMPRSS6 monoclonal antibody, sharply reduced...
Tempus AI (Nasdaq: TEM) secured up to USD 9.5 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop and clinically validate an...
Roche (SIX: RO; OTCQX: RHHBY) announced a US FDA Priority Review award for a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab),...
A protein arginine methyltransferase acts as a previously unrecognized suppressor of cytotoxic T cell proliferation, offering a potential new target for...
Lee's Pharmaceutical Holdings (HKEX: 00950) has licensed exclusive rights to develop, manufacture, and commercialize OC-3, a preclinical selective PARP1...
A Nature publication has given South San Francisco-based Apeximmune Therapeutics substantial external validation, with two independent research teams...
San Carlos, California-based TwoStep Therapeutics has raised USD 62.5 million in an oversubscribed Series A financing round, coinciding with US FDA...
Alebund Pharmaceuticals (HKEX: 09637) received US FDA clearance of its investigational new drug (IND) application for AP308, an engineered recombinant IgA...
San Francisco-based IDEAYA Biosciences (Nasdaq: IDYA) and France-based Servier announced that the first patient has been dosed in OptimUM-11, a global Phase...
Free, systematic R&D and deal news. Daily.